FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted

Vallejo-Blanco, A. (Adrián); Erice, O. (Oihane); Entrialgo-Cadierno, R. (Rodrigo); Feliu, I. (Iker); Guruceaga, E. (Elizabeth); Perugorria, M.J. (María J.); Olaizola, P. (Paula); Muggli, A. (Alexandra); Macaya, I. (Irati); O’Dell, M. (Michael); Ruiz-Fernandez-de-Cordoba, B. (Borja); Ortiz-Espinosa, S. (Sergio); Hezel, A.F. (Aram F.); Arozarena, I. (Imanol); Lecanda, F. (Fernando); Avila, M.A. (Matías Antonio); García-Fernández-de-Barrena, M. (Maite); Evert, M. (Matthias); Ponz-Sarvise, M. (Mariano); Calvisi, D.F. (Diego F.); Banales, J.M. (Jesús M.); Vicent, S. (Silvestre)

Keywords:

FOSL1
Cholangiocarcinoma
Transcription factors
Genetics
Targeted therapies

Issue Date:

2021

Publisher:

Elsevier

ISSN:

0168-8278

Note:

This is an open access article under the CC BY-NC-ND license.

Citation:

Vallejo-Blanco, A. (Adrián); Erice, O. (Oihane); Entrialgo-Cadierno, R. (Rodrigo); et al. "FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted". Journal of Hepatology. 75 (2), 2021, 363 - 376

Abstract

Understanding the molecular mechanisms involved in cholangiocarcinoma (bile duct cancer) development and progression stands as a critical step for the development of novel therapies. Through an inter-species approach, this study provides evidence of the clinical and functional role of the transcription factor FOSL1 in cholangiocarcinoma. Moreover, we report that downstream effectors of FOSL1 are susceptible to pharmacological inhibition, thus providing new opportunities for therapeutic intervention.

URI:

https://hdl.handle.net/10171/63351

DOI:

10.1016/j.jhep.2021.03.028

Appears in Collections:

DA - Ciencias - HAP - Artículos de revista
DA - CIMA - Hepatología - Hepatología del cáncer - Artículos de revista
DA - CIMA - Tumores sólidos y biomarcadores- Adhesión y metástasis - Artículos de revista
DA - CUN - Oncología médica - Artículos de revista

Files in This Item: